Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Nuvaxovid JN.1 vaccine in older and high-risk participants
2025-000541-19Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Primary endpoint: Pseudovirus neutralization geometric mean fold rise against Omicron LP.8.1 at Day 28.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2025-000541-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000541-19.